» Articles » PMID: 31423643

Systemic Immune-inflammation Index Acts As a Novel Diagnostic Biomarker for Postmenopausal Osteoporosis and Could Predict the Risk of Osteoporotic Fracture

Overview
Journal J Clin Lab Anal
Publisher Wiley
Date 2019 Aug 20
PMID 31423643
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Postmenopausal osteoporosis (PMOP) is a bone metabolism disorder involving systematic inflammation activation. Blood routine examination is easily available in clinical practice and contains abundant information reflecting the systematic inflammation level. Thus, it is attractive to achieve early diagnosis of PMOP and predict osteoporotic fracture risk just based on the biomarkers in blood routine examination.

Methods: A multi-centric prospective cohort study was designed and enrolled postmenopausal women from two independent institutions. All participants underwent the dual-energy X-ray absorptiometry (DEXA) scanning for diagnosing PMOP. Blood routine examination was conducted, and the key inflammatory biomarkers such as neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) were calculated. PMOP patients were followed up to observe osteoporotic fracture and identify the related risk predictors.

Results: A total of 92 participants out of 238 enrolled postmenopausal women were diagnosed with PMOP, with a prevalence of 38.66%. The main risk factors identified for PMOP included older age (OR = 2.06, 95% CI = 1.14-3.72), longer menopause duration (OR = 3.14, 95% CI = 2.06-4.79), higher NLR (OR = 2.11, 95% CI = 1.37-3.25), and higher SII (OR = 3.02, 95% CI = 1.98-4.61). Besides age and menopause duration, SII ≥834.89 was newly identified as a prominent risk factor for discriminating osteoporotic fracture risk in PMOP patients (HR = 3.66, 95% CI = 1.249-10.71).

Conclusion: As an easy and economical biomarker calculated from blood routine examination, SII not only acts as a good risk predictor for PMOP diagnosis but also well discriminates the osteoporotic fracture risk, which deserves further investigation and application in clinical practice.

Citing Articles

Association between systemic immune-inflammation index and trimethylamine N-oxide levels in peripheral blood and osteoporosis in overweight and obese patients.

Li L, An J, Bai J, Zhang Y, Li X, Lv H Front Endocrinol (Lausanne). 2025; 16:1539594.

PMID: 40017693 PMC: 11864960. DOI: 10.3389/fendo.2025.1539594.


Systemic immune-inflammation index to albumin (SII/ALB) ratio as a novel dual-dimensional powerful predictor for hip fractures in elderly females with diabetes: a postmenopausal longitudinal cohort study.

Lu J, Wei F, Sun J, Zhai Z, Pan J, Huang S BMC Endocr Disord. 2025; 25(1):57.

PMID: 40016771 PMC: 11869492. DOI: 10.1186/s12902-025-01889-1.


Associations between systemic inflammation response index and femur bone mineral density in adults: The NHANES 2005-2010, 2013-2014, and 2017-2018.

Ye X, Li X, Zhu C, Cui L, Shen Z, Xu K Medicine (Baltimore). 2025; 104(8):e41565.

PMID: 39993115 PMC: 11856988. DOI: 10.1097/MD.0000000000041565.


Immune-nutritional indicators predict short-term mortality in older patients after emergency gastrointestinal surgery: a retrospective study.

Jin Z, Yang T, Wang Z BMC Gastroenterol. 2025; 25(1):99.

PMID: 39984877 PMC: 11844028. DOI: 10.1186/s12876-024-03583-3.


Systemic immune-inflammatory index predicts fragility fracture risk in postmenopausal anemic females with type 2 diabetes mellitus: evidence from a longitudinal cohort study.

Huang D, He Q, Pan J, Zhai Z, Sun J, Wang Q BMC Endocr Disord. 2024; 24(1):256.

PMID: 39604954 PMC: 11600564. DOI: 10.1186/s12902-024-01792-1.


References
1.
Oka R, Ohira M, Suzuki S, Yoshida T, Koide H, Tanaka T . Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey. Endocr J. 2017; 65(2):193-202. DOI: 10.1507/endocrj.EJ17-0331. View

2.
Eastell R, Szulc P . Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017; 5(11):908-923. DOI: 10.1016/S2213-8587(17)30184-5. View

3.
Kanis J, McCloskey E, Johansson H, Cooper C, Rizzoli R, Reginster J . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2012; 24(1):23-57. PMC: 3587294. DOI: 10.1007/s00198-012-2074-y. View

4.
Baccaro L, Conde D, Costa-Paiva L, Pinto-Neto A . The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging. 2015; 10:583-91. PMC: 4374649. DOI: 10.2147/CIA.S54614. View

5.
Fang H, Zhang H, Wang Z, Zhou Z, Li Y, Lu L . Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture. J Clin Lab Anal. 2019; 34(1):e23016. PMC: 6977145. DOI: 10.1002/jcla.23016. View